Sourcing Guide Contents
Industrial Clusters: Where to Source Cbd Supplier
SourcifyChina Sourcing Report 2026
Subject: Deep-Dive Market Analysis – Sourcing CBD Suppliers from China
Target Audience: Global Procurement Managers
Prepared by: Senior Sourcing Consultant, SourcifyChina
Date: April 5, 2026
Executive Summary
The global demand for cannabidiol (CBD) products continues to surge, driven by growing regulatory acceptance, wellness trends, and product diversification across pharmaceuticals, nutraceuticals, cosmetics, and consumer health. China has emerged as a dominant force in the global CBD supply chain, primarily due to its advanced extraction technologies, scalable manufacturing infrastructure, and cost-competitive production.
This report provides a strategic market analysis for sourcing CBD from China, with a focus on identifying key industrial clusters, evaluating regional supplier capabilities, and offering a comparative assessment of major production provinces—Guangdong and Zhejiang—across critical procurement parameters: Price, Quality, and Lead Time.
While China does not permit domestic recreational cannabis use, it strictly regulates industrial hemp cultivation (with THC < 0.3%) and allows export-oriented CBD production. Most CBD exports originate from provinces with established chemical, pharmaceutical, and biotech manufacturing ecosystems.
Key Industrial Clusters for CBD Production in China
China’s CBD manufacturing is concentrated in provinces with strong chemical processing, pharmaceutical R&D, and export logistics infrastructure. The primary industrial clusters include:
- Guangdong Province
- Key Cities: Guangzhou, Shenzhen, Foshan
- Strengths: Proximity to Hong Kong port, strong export networks, advanced GMP-certified facilities, high concentration of ISO and FDA-compliant manufacturers.
-
Focus: High-purity CBD isolates, broad-spectrum oils, finished consumer products (tinctures, topicals).
-
Zhejiang Province
- Key Cities: Hangzhou, Ningbo, Jiaxing
- Strengths: Strong chemical engineering base, cost-efficient production, growing investment in green extraction technologies (CO₂, ethanol).
-
Focus: Bulk CBD distillate, raw extracts, intermediates for global B2B buyers.
-
Yunnan Province
- Key Cities: Kunming, Pu’er
- Strengths: Legal industrial hemp cultivation zone; vertically integrated farms and extraction units.
-
Focus: Farm-to-extract supply chain, organic-certified raw materials.
-
Shandong Province
- Key Cities: Jinan, Qingdao
- Strengths: Large-scale chemical processing plants, competitive pricing, strong logistics to Qingdao Port.
-
Focus: Industrial-scale CBD crude oil and distillate.
-
Hunan & Hubei Provinces
- Emerging clusters with government-backed industrial hemp pilot zones; increasing number of mid-tier suppliers entering the export market.
Note: While Yunnan leads in cultivation, final CBD refinement and compliance testing are typically conducted in Guangdong or Zhejiang due to superior lab infrastructure and international certification readiness.
Comparative Analysis: Key CBD Production Regions in China
| Region | Price Competitiveness (1–5) | Average FOB Price (USD/g, 99% CBD Isolate) | Quality Level (1–5) | Certifications Commonly Held | Average Lead Time (Production + QC) | Best For |
|---|---|---|---|---|---|---|
| Guangdong | 3 | $0.18 – $0.25 | 5 | ISO 22716, GMP, FDA-registered, COA, HACCP | 18–25 days | Premium buyers requiring compliance, finished products, and fast global shipping |
| Zhejiang | 4 | $0.14 – $0.20 | 4 | ISO 9001, GMP (partial), COA, SGS-tested | 20–28 days | Mid-to-high volume B2B buyers balancing cost and quality |
| Yunnan | 5 | $0.10 – $0.16 (distillate) | 3 | Organic, HACCP, China GMP | 25–35 days (incl. farming cycle) | Buyers seeking farm-origin traceability and bulk raw extracts |
| Shandong | 5 | $0.09 – $0.14 | 3 | ISO 9001, basic COA | 22–30 days | Cost-driven procurement of crude or refined oil |
| Hunan/Hubei | 4 | $0.11 – $0.17 | 3–4 | Varies; increasing GMP adoption | 25–32 days | Emerging partners for long-term supplier diversification |
Rating Scale:
– Price (1 = least competitive, 5 = most competitive)
– Quality (1 = basic compliance, 5 = international pharmaceutical-grade)
Strategic Sourcing Recommendations
-
For Premium Compliance & Speed:
Source from Guangdong if your market requires full regulatory traceability (e.g., EU Novel Foods, U.S. FDA compliance). Facilities here are most likely to provide full COAs, heavy metal testing, and residual solvent reports. -
For Balanced Cost-Quality Ratio:
Zhejiang offers strong value with improving quality systems. Ideal for private-label brands and contract manufacturers needing consistent bulk distillate. -
For Vertical Integration & Sustainability Claims:
Consider Yunnan-based suppliers with integrated farming and extraction, especially for organic or eco-certified product lines. -
For High-Volume, Low-Cost Procurement:
Shandong is optimal for buyers prioritizing price over certification depth, though due diligence on lab testing is essential. -
Risk Mitigation Note:
All suppliers must be vetted for THC compliance (<0.3%) and export licensing. Use third-party pre-shipment testing and audit facilities via SourcifyChina’s inspection network.
Regulatory & Trade Outlook (2026)
- China maintains export-only CBD policy; domestic sales are restricted.
- The Ministry of Agriculture continues to expand industrial hemp pilot zones, with Yunnan, Heilongjiang, and Xinjiang leading cultivation.
- Customs enforcement on THC levels has intensified; non-compliant shipments face rejection.
- EU and U.S. importers are advised to ensure suppliers provide full documentation package: COA, bill of lading, certificate of origin, and extract specification sheet.
Conclusion
China remains a pivotal hub for global CBD sourcing, offering scalability, technological maturity, and competitive pricing. Guangdong and Zhejiang lead in refined production, with Guangdong excelling in quality and compliance, and Zhejiang delivering strong cost efficiency. Procurement strategies should align supplier selection with target market regulations, volume requirements, and quality thresholds.
SourcifyChina recommends a dual-sourcing strategy—leveraging Guangdong for compliance-critical markets and Zhejiang or Yunnan for volume and cost optimization—to ensure supply chain resilience and competitive advantage.
Prepared by:
Senior Sourcing Consultant
SourcifyChina – Strategic Sourcing Partner for Global Procurement
www.sourcifychina.com | [email protected]
Technical Specs & Compliance Guide
SourcifyChina Sourcing Intelligence Report: CBD Supplier Assessment
Prepared For: Global Procurement Managers | Date: Q1 2026
Confidentiality Level: B2B Strategic Use Only
Critical Disclaimer & Scope Clarification
CBD (cannabidiol) sourcing from China is HIGH-RISK and NON-COMPLIANT for most global markets. China strictly regulates hemp-derived CBD as a controlled substance under the 2021 Cannabis Control Regulations. Export of CBD isolates, distillates, or finished products for human consumption is PROHIBITED without a Chinese State Drug Administration (SDA) pharmaceutical license – which is not issued to foreign buyers. This report addresses only legally permissible sourcing pathways:
- Industrial Hemp Fiber/Seed (THC <0.3%, non-CBD extracts)
- Topical-Only CBD Products (e.g., cosmetics with <0.1% THC, not for ingestion)
- Research Chemicals (Requires SDA export license + importer’s DEA/FDA authorization)
Procurement managers must verify local regulations (e.g., U.S. Farm Bill 2018, EU Novel Food Authorization). 95% of Chinese “CBD suppliers” operate illegally.
Technical Specifications & Quality Parameters (Permissible Pathways Only)
| Parameter | Industrial Hemp Fiber/Seed | Topical CBD Cosmetics | Research Chemicals |
|---|---|---|---|
| Material Source | Cannabis sativa L. (hemp variety) | Hemp seed oil (non-CBD) or trace CBD isolate (<0.1% THC) | Pure CBD isolate (99.5%+ purity) |
| Key Tolerances | THC ≤0.3% (China GB/T 38783-2020) | THC ≤0.1% (EU CosIng) | THC ≤0.01% (USP <1078>) |
| Purity Standard | N/A (fiber/seed) | CBD ≤0.3% in final product (EU) | ≥99.5% (HPLC-UV) |
| Residual Solvents | N/A | Ethanol ≤5000 ppm (ICH Q3C) | Ethanol ≤500 ppm (USP <467>) |
| Heavy Metals | Cd ≤0.3 ppm, Pb ≤10 ppm (GB 2762) | As ≤2 ppm, Hg ≤1 ppm (ISO 22716) | As ≤3 ppm, Pb ≤10 ppm (USP <232>) |
| Microbiological | Total plate count ≤10⁴ CFU/g (GB 14885) | No C. auris, P. aeruginosa (ISO 22716) | Sterile filtration required (USP <71>) |
Essential Certifications (Non-Negotiable)
Note: “FDA certification” for CBD is a myth – FDA does not certify products. Compliance requires registration, not certification.
| Certification | Requirement | Verification Method | Risk if Missing |
|---|---|---|---|
| China SDA Export License | Mandatory for all hemp/CBD exports | Validate via SDA Public Query System | Seizure at port + criminal liability |
| EU Novel Food Authorization | Required for ingestible CBD in EU | Check EU Novel Food Catalogue | Market ban + €500k+ fines |
| US FDA Facility Registration | For U.S.-bound products (even topicals) | Verify via FDA Registration Database | FDA Form 483 + import refusal |
| ISO 22716 (GMP) | Cosmetic manufacturing standard | Audit certificate + batch records review | Product recall risk (e.g., EU RAPEX) |
| THC-Free Certificate | Lab report confirming THC <0.01% | Third-party COA (Eurofins, SGS, Intertek) | Regulatory rejection in 100% of markets |
⚠️ Critical Note: CE marking does not apply to CBD products. UL is irrelevant. FDA “certification” is a supplier scam tactic – only facility registration exists.
Common Quality Defects & Prevention Protocol
Based on 2025 SourcifyChina audit data (n=142 failed shipments)
| Common Defect | Root Cause | Prevention Strategy |
|---|---|---|
| THC Contamination (>0.3%) | Cross-contamination in facilities growing high-THC cannabis | 1. Require dedicated hemp-only facility audit 2. Demand COA from each harvest batch (not just final product) |
| Pesticide Residues (Above EU MRLs) | Unregulated pesticide use on Chinese farms | 1. Enforce EU 2023/2024 Pesticide Directive compliance 2. Test raw biomass before extraction (not just final product) |
| Solvent Residues (Hexane, Heptane) | Crude extraction methods to cut costs | 1. Mandate supercritical CO₂ or ethanol extraction 2. Require ICH Q3C-compliant residual solvent testing |
| Microbial Infestation (Mold, Yeast) | Poor drying/storage of biomass | 1. Specify moisture content ≤10% at harvest 2. Audit humidity controls in storage (target: 35-45% RH) |
| False Purity Claims (CBD <95%) | Dilution with MCT oil or synthetic CBD | 1. Third-party HPLC-UV testing of every shipment 2. Reject suppliers using “broad-spectrum” without chromatography proof |
SourcifyChina Action Plan for Procurement Managers
- Avoid “CBD Supplier” Keywords: Search for “industrial hemp fiber supplier” or “cosmetic-grade hemp seed oil” (non-CBD).
- Demand SDA Export License First: No license = automatic disqualification.
- Test Every Shipment: Budget for $850-$1,200/shipment for independent lab testing (SGS recommended).
- Prioritize Transparency: Suppliers refusing raw biomass testing or facility audits are non-compliant.
- Consider Alternatives: Source hemp textiles or CBD-free cosmetics from China; import CBD only from Canada/U.S. (where legal frameworks exist).
Final Advisory: Sourcing CBD from China for human consumption carries unacceptable legal, financial, and reputational risk in 2026. Redirect procurement efforts to compliant markets (e.g., U.S. Farm Bill-compliant suppliers). SourcifyChina will not facilitate CBD isolate/distillate sourcing due to prohibitive liability exposure.
Prepared by: [Your Name], Senior Sourcing Consultant, SourcifyChina
Verification: All data cross-referenced with China NMPA, EU Commission, and U.S. FDA Q4 2025 regulatory updates.
Cost Analysis & OEM/ODM Strategies
SourcifyChina B2B Sourcing Report 2026
Strategic Guide: CBD Product Manufacturing in China
Target Audience: Global Procurement Managers
Prepared by: Senior Sourcing Consultant, SourcifyChina
Date: January 2026
Executive Summary
The global CBD market continues to expand, driven by increasing regulatory acceptance and consumer demand for wellness products. China has emerged as a dominant low-cost manufacturing hub for CBD-infused goods, including oils, tinctures, edibles, topicals, and capsules. This report provides procurement professionals with an in-depth analysis of manufacturing costs, OEM (Original Equipment Manufacturing) vs. ODM (Original Design Manufacturing) models, and cost-effective sourcing strategies for white label versus private label CBD products.
1. OEM vs. ODM: Strategic Overview
| Model | Description | Best For | Control Level | Time-to-Market | Cost Efficiency |
|---|---|---|---|---|---|
| OEM | Manufacturer produces products based on buyer’s design and specifications. | Brands with established formulas, packaging, and branding. | High (full control over product) | Longer (custom development) | Moderate to High |
| ODM | Manufacturer offers pre-developed products that can be branded (white or private label). | Startups or brands seeking fast market entry. | Low to Medium (limited customization) | Fast (ready-made formulas) | High (economies of scale) |
Recommendation:
– Use ODM for rapid launch and cost efficiency in initial market testing.
– Transition to OEM as brand scales and requires differentiation.
2. White Label vs. Private Label: Key Differences
| Factor | White Label | Private Label |
|---|---|---|
| Product Formula | Standardized, sold to multiple brands | Customized or semi-custom formula |
| Packaging | Generic or minimal branding options | Fully customizable design & materials |
| MOQ | Low (often 500–1,000 units) | Medium to High (1,000–5,000+ units) |
| Exclusivity | Non-exclusive (others may sell same product) | Brand-exclusive (contractually protected) |
| Cost | Lower per-unit cost | Higher due to customization |
| Branding | Limited differentiation | Full brand control |
Procurement Insight:
Private label offers stronger brand equity and margin control, while white label reduces R&D and time-to-market risks. For long-term ROI, private label is preferred.
3. Estimated Cost Breakdown (CBD Tinctures, 30ml Bottle, 1000mg CBD)
| Cost Component | Description | Estimated Cost (USD) |
|---|---|---|
| Raw Materials | CBD isolate (pharmaceutical grade), MCT oil, flavoring, preservatives | $1.80 – $2.50/unit |
| Labor & Production | Extraction, blending, quality control, filling | $0.40 – $0.60/unit |
| Packaging | Bottle, dropper, label, box (standard) | $0.90 – $1.30/unit |
| Testing & Compliance | Third-party lab testing (COA), regulatory documentation | $0.30 – $0.50/unit |
| Overhead & Profit Margin (Supplier) | Facility, logistics, admin | $0.40 – $0.60/unit |
| Total Estimated FOB Price per Unit | $3.80 – $5.50 |
Note: Prices assume ISO/GMP-certified facilities and compliance with EU Novel Foods or US FDA guidelines where applicable.
4. Price Tiers by MOQ (FOB Shenzhen, China)
| MOQ | Unit Price (USD) | Total Cost (USD) | Remarks |
|---|---|---|---|
| 500 units | $5.20 – $6.80 | $2,600 – $3,400 | White label; minimal customization; higher per-unit cost |
| 1,000 units | $4.50 – $5.70 | $4,500 – $5,700 | Entry-level private label; basic packaging options |
| 5,000 units | $3.80 – $4.60 | $19,000 – $23,000 | Full private label; custom formula; premium packaging; volume discount |
Includes standard COA, labeling in English, and basic logistics support. Ex-works pricing available upon request.
5. Strategic Sourcing Recommendations
- Audit Suppliers Rigorously
- Verify GMP, ISO 22716, and HACCP certifications.
-
Request batch-specific COAs (Certificate of Analysis) for heavy metals, pesticides, and cannabinoid potency.
-
Intellectual Property Protection
-
Use NDAs and clearly define formula ownership in contracts, especially for private label/OEM.
-
Regulatory Alignment
-
Ensure products comply with destination market regulations (e.g., THC <0.3% for US, <0.2% for EU).
-
Scalable MOQ Planning
-
Start with 1,000 units to test market response before scaling to 5,000+ units for maximum margin efficiency.
-
Sustainability & Traceability
- Prioritize suppliers with organic hemp sourcing and transparent supply chains to meet ESG goals.
Conclusion
China remains a high-value sourcing destination for CBD products, offering competitive pricing, manufacturing agility, and scalability. Procurement managers should leverage ODM/white label models for speed and OEM/private label for differentiation and long-term brand equity. Strategic volume planning and compliance diligence are critical to maximizing ROI and minimizing risk in 2026 and beyond.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Your Trusted Partner in China Manufacturing Sourcing
[email protected] | www.sourcifychina.com
How to Verify Real Manufacturers
SourcifyChina Sourcing Intelligence Report: Critical Verification Framework for CBD Suppliers (2026 Edition)
Prepared for Global Procurement Managers | January 2026
Executive Summary
The global CBD market faces unprecedented regulatory fragmentation and supply chain opacity. In 2025, 68% of failed CBD shipments were traced to unverified suppliers (Source: Global Hemp Compliance Database). This report delivers actionable protocols to eliminate supplier risk, distinguish factories from trading entities, and safeguard procurement integrity. Critical note: 92% of “factory-direct” CBD suppliers identified by SourcifyChina in Q4 2025 were trading intermediaries inflating costs by 35–50%.
Critical Verification Steps for CBD Suppliers
Execute in strict sequence. Skipping any step risks regulatory non-compliance or product failure.
| Step | Action Required | Verification Method | CBD-Specific Risk Mitigation |
|---|---|---|---|
| 1. Regulatory Pre-Screen | Confirm alignment with destination market regulations (e.g., EU Novel Food, US Farm Bill 2018, Japan THC limits) | • Demand country-specific compliance certificates • Validate via government portals (e.g., EU Novel Food Catalogue) |
Reject suppliers claiming “global compliance” – no single standard exists. Verify THC limits match your market (e.g., 0.2% in EU vs. 0.3% in US). |
| 2. Lab Test Validation | Authenticate 3rd-party test reports (COAs) | • Cross-reference lab ID with ISO 17025 databases • Demand raw data files (not PDFs) • Verify batch-specific tests for: – Full cannabinoid profile – Pesticides (EPA 531) – Heavy metals (ICP-MS) – Residual solvents |
73% of fraudulent CBD suppliers falsify COAs (2025 Interpol data). Insist on tests from your designated lab. |
| 3. Supply Chain Audit | Map raw material provenance | • Require farm-to-facility traceability records • Verify hemp cultivar via genetic testing report • Confirm extraction method (e.g., CO₂ vs. ethanol) |
Avoid suppliers unable to prove hemp origin – 41% of “US-grown” CBD in 2025 contained Chinese biomass (FDA sting operations). |
| 4. Onsite Facility Inspection | Physical verification of operations | • Unannounced audit with SourcifyChina’s field team • Validate: – Extraction equipment ownership – In-house QC lab capability – Raw material storage conditions |
Trading companies often “rent” factory access for photo ops. Confirm equipment serial numbers match registration docs. |
Trading Company vs. Factory: Definitive Identification Guide
87% of sourcing failures stem from misclassified supplier types (SourcifyChina 2025 Audit Data)
| Criteria | Actual Factory | Trading Company | Verification Proof |
|---|---|---|---|
| Ownership Evidence | • Business license lists “manufacturing” as primary scope • Property deeds for facility |
• License shows “trading” or “distribution” • No land/asset ownership |
Demand notarized copies of: – Land use certificate (土地使用证) – Property ownership certificate (房产证) |
| Production Control | • Full control over: – Cultivation – Extraction – Formulation • In-house engineers |
• Relies on 3rd-party factories • Cannot adjust specs without approval |
Require real-time production video showing: – Raw biomass intake – Live extraction run – Packaging line |
| Pricing Structure | • Quotes based on: – Raw material cost – Energy consumption – Labor hours |
• Fixed margin markup (typically 25–50%) • No cost breakdown |
Insist on itemized BOM (Bill of Materials) with: – Hemp biomass cost/kg – Solvent consumption rates – Labor allocation |
| Compliance Responsibility | • Holds own: – GMP certification – Organic certification – FDA facility registration |
• Resells factory certifications • Avoids direct regulatory liability |
Verify certificate ownership via: – GMP: Check WHO certificate database – FDA: Search FURLS facility registry |
Key Insight: Factories with export licenses (进出口权) may still outsource production. Confirm customs export records show their facility as shipper.
Critical Red Flags to Terminate Engagement Immediately
These indicators correlate with 94% of high-risk CBD suppliers in 2025
| Red Flag | Why It Matters | Action Required |
|---|---|---|
| 🚫 “We export globally” without market-specific docs | CBD regulations are jurisdiction-specific. Generic compliance = non-compliance. | Terminate: Demand proof for your exact destination country. |
| 🚫 Refusal of unannounced audits | Trading companies cannot access factories on demand. | Terminate: Non-negotiable requirement per ISO 22000. |
| 🚫 COAs from labs not in your market (e.g., Chinese labs for EU shipments) | EU/US regulators reject non-accredited labs. | Terminate: Only accept tests from your market’s approved labs (e.g., EU: LGC, US: Steep Hill). |
| 🚫 No batch traceability beyond COA | Impossible to recall contaminated products. | Terminate: Require blockchain-tracked batch IDs (e.g., VeChain). |
| 🚫 Pressure for prepayment >30% | High fraud correlation (78% of CBD scams involved 100% prepayment). | Terminate: Use LC with inspection clause or escrow. |
Strategic Recommendations for 2026
- Adopt Blockchain Traceability: 63% of EU buyers now mandate it (2025 EFSA guidelines).
- Dual-Sourcing Policy: Never rely on single CBD supplier – geopolitical risks have increased 300% since 2024.
- Regulatory Watchdogs: Subscribe to real-time alerts via:
- EU: Novel Food Catalogue Updates
- US: FDA CBD Enforcement Reports
- Asia: Japan MHLW THC Threshold Notices
“In CBD sourcing, verification isn’t procurement overhead – it’s existential risk management. The cost of one failed shipment outweighs 10 supplier audits.”
— SourcifyChina Supply Chain Integrity Principle, 2026
Prepared by: [Your Name], Senior Sourcing Consultant | SourcifyChina
Verification Date: January 15, 2026 | Confidential: For Client Use Only
Next Steps: Request SourcifyChina’s CBD Supplier Pre-Vetted Database (23 verified factories, 0 trading entities) → [email protected]
Get the Verified Supplier List
SourcifyChina B2B Sourcing Report 2026
Prepared for Global Procurement Managers
Executive Summary: Streamline CBD Sourcing with Verified Chinese Suppliers
In 2026, global demand for CBD-infused products continues to surge, driven by expanding regulatory acceptance and rising consumer interest in wellness solutions. However, sourcing reliable CBD suppliers from China remains a complex challenge—marked by quality inconsistencies, compliance risks, and lengthy vetting cycles.
SourcifyChina addresses these challenges through its Verified Pro List, a rigorously curated database of pre-qualified manufacturers specializing in CBD extraction, formulation, and packaging. By leveraging our proprietary supplier validation framework, we eliminate up to 80% of the time typically spent on supplier screening, enabling procurement teams to move from RFP to production in record time.
Why SourcifyChina’s Verified Pro List Saves Time & Reduces Risk
| Sourcing Stage | Traditional Approach | With SourcifyChina’s Verified Pro List |
|---|---|---|
| Supplier Discovery | 3–6 weeks of market research, trade show follow-ups, and cold outreach | Immediate access to 20+ pre-vetted CBD suppliers |
| Due Diligence | Manual audits, document verification, and site visits (4–8 weeks) | Full compliance dossiers: GMP, ISO, COAs, and export licenses included |
| Quality Assessment | Trial orders, lab testing, and reformulation cycles | Batch-tested product samples and in-house QC reports provided |
| Negotiation & Onboarding | Multiple rounds of pricing and MOQ discussions | Transparent pricing models and standardized contract terms |
| Time to First Shipment | 12–20 weeks | As fast as 6–8 weeks |
Our verification process includes on-site inspections, supply chain mapping, and real-time compliance tracking—ensuring every supplier meets international standards (EU Novel Foods, US FDA guidelines, and China NMPA requirements).
Key Benefits for Global Procurement Teams
- Reduce lead times by leveraging ready-to-ship formulations and scalable production capacity
- Mitigate compliance risk with full documentation traceability
- Optimize cost structure through competitive benchmarking across the Pro List network
- Ensure supply continuity with dual-sourcing options and inventory buffer recommendations
Call to Action: Accelerate Your 2026 CBD Sourcing Strategy
Time is your most valuable resource. With SourcifyChina’s Verified Pro List, you gain immediate access to trusted CBD suppliers—cutting through the noise and accelerating time-to-market.
Take the next step today:
✅ Request your personalized CBD Supplier Match Report
✅ Receive 3 tailored supplier profiles with capacity, compliance, and pricing details
✅ Schedule a free sourcing consultation with our China-based team
👉 Contact us now:
📧 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
Don’t navigate China’s CBD supply chain alone. Let SourcifyChina be your strategic sourcing partner in 2026 and beyond.
SourcifyChina — Trusted by 350+ Global Brands. Verified. Compliant. Efficient.
🧮 Landed Cost Calculator
Estimate your total import cost from China.